Polen Capital acquired 13.5 Million Abbott Laboratories shares worth $1.44 Billion. That's 3.37% of their equity portfolio (12th largest holding). The first Abbott Laboratories trade was made in Q3 2013. Since then Polen Capital bought shares sixteen more times and sold shares on thirteen occasions. The stake costed the investor $1.21 Billion, netting the investor a gain of 20% so far.
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first quarter 2024 investor letter. A copy of the same can be dow...
Insider Monkey, 5 days agoAristotle Capital Management LLC decreased its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 12.1% in the second quarter, according to the comp...
The AM Reporter, 5 months ago… 69.62%. Abbott Laboratories Company Profile (Free Report) Abbott Laboratories , together with … in four segments: Established Pharmaceutical Products, Diag...
EIN News Pharmaceuticals, 6 months ago… 24th. Wolfe Research upgraded Abbott Laboratories from an “underperform” rating … on ABT Abbott Laboratories Company Profile (Free Report) Abbott Laborator...
EIN News Pharmaceuticals, 7 months ago